Pavel Hurník

Dr. Pavel Hurník


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2023 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
PHPavel Hurník
Pavel Hurník
BPBarbora Moldovan Putnová
Barbora Moldovan Putnová
TSTereza Sevcikova
Tereza Sevcikova
EHEva Hrubá
Eva Hrubá
IPIveta Putnová
Iveta Putnová
JSJan Stembirek
Jan Stembirek
Background: Ameloblastic carcinoma and metastasising ameloblastoma are rare epithelial odontogenic tumours with aggressive features. Distinguishing between these two lesions is often clinically difficult but necessary to predict tumour behaviour or to plan future therapy. Here, we provide a brief review of the literature available on these two types of lesions and present a new case report of a young man with an ameloblastoma displaying metastatic features. We also use this case to illustrate the similarities and differences between these two types of tumours and the difficulties of their differential diagnosis. Case presentation: Our histopathological analyses uncovered a metastasising tumour with features of ameloblastic carcinoma, which developed from the ameloblastoma. We profiled the gene expression of Wnt pathway members in ameloblastoma sample of this patient, because multiple molecules of this pathway are involved in the establishing of cell polarity, cell migration or for epithelial–mesenchymal transition during tumour metastasis to evaluate features of tumor behaviour. Indeed, we found upregulation of several cell migration–related genes in our patient. Moreover, we uncovered somatic mutation BRAF p.V600E with known pathological role in cancerogenesis and germline heterozygous FANCA p.S858R mutation, whose interpretation in this context has not been discussed yet. Conclusions: In conclusion, we have uncovered a unique case of ameloblastic carcinoma associated with an alteration of Wnt signalling and the presence of BRAF mutation. Development of harmful state of our patient might be also supported by the germline mutation in one FANCA allele, however this has to be confirmed by further analyses.

16 October 2017 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
JVJana Vaculova
Jana Vaculova
Jiri GalloJiri Gallo
Jiri Gallo
PHPavel Hurník
Pavel Hurník
OMOldřich Motyka
Oldřich Motyka
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
JDJana Dvorackova
Jana Dvorackova

29 June 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
TBTomáš Blažek
Tomáš Blažek
ZČZuzana Zděblová Čermáková
Zuzana Zděblová Čermáková
LKLukáš Knybel
Lukáš Knybel
PHPavel Hurník
Pavel Hurník
JSJan Stembirek
Jan Stembirek
RSRenata Soumarová
Renata Soumarová
Purpose: We evaluated the efficiency and toxicity of stereotactic hypofractionated boost in combination with conventionally fractionated radiotherapy in the treatment of advanced floor of the mouth cancer. Methods: Thirty-seven patients with advanced stage of the floor of the mouth cancer, histologically confirmed squamous cell carcinoma (p16 negative) ineligible for surgical treatment, were indicated for radiochemotherapy or hyperfractionated accelerated radiotherapy (HART). The radiotherapy protocol combined external beam radiotherapy (EBRT) and a stereotactic hypofractionated boost to the primary tumor. The dose delivered from EBRT was 70–72.5 Gy in 35/50 fractions. The hypofractionated boost followed with 10 Gy in two fractions. For the variables—tumor volume, stage and grade a multivariate analysis was performed to find the relationship between overall survival, local progression and metastasis. Toxicity was evaluated according to CTCAE scale version 4. Results: After a median follow-up of 16 months, 23 patients (62%) achieved complete remission. The median time to local progression and metastasis was 7 months. Local control (LC) at 2 and 5-years was 70% and 62%, respectively. Progression-free survival (PFS) and overall survival (OS) were 57% and 49% at 2 years and 41% and 27% at 5 years, respectively. Statistical analysis revealed that larger tumors had worse overall survival and a greater chance of metastasis. Log-Rank GTV > 44 ccm (HR = 1.96; [95% CI (0.87; 4.38)]; p = 0.11). No boost-related severe acute toxicity was observed. Late osteonecrosis was observed in 3 patients (8%). Conclusion: The combination of EBRT and stereotactic hypofractionated boost is safe and seems to be an effective option for dose escalation in patients with advanced floor of the mouth tumors who are ineligible for surgical treatment and require a non-invasive approach.

1 August 2019 in Parasitology International
Verified
Journal Article
Closed access
PHPavel Hurník
Pavel Hurník
DŽD. Žiak
D. Žiak
JDJ. Dluhošová
J. Dluhošová
VŽV. Židlík
V. Židlík
JŠJ. Šustíková
J. Šustíková
ENEva Nohýnková
Eva Nohýnková

1 July 2019 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
Milan UríkMilan Urík
Milan Urík
PHPavel Hurník
Pavel Hurník
DŽDušan Žiak
Dušan Žiak
JMJosef Machač
Josef Machač
IŠIvo Šlapák
Ivo Šlapák
PJPetr Jabandžiev
Petr Jabandžiev

1 July 2016 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
Milan UríkMilan Urík
Milan Urík
PHPavel Hurník
Pavel Hurník
DŽD. Žiak
D. Žiak
JMJ. Machač
J. Machač
IŠI. Šlapák
I. Šlapák
JDJ. Dvořáčková
J. Dvořáčková